Norris Cotton Cancer Center Conducts Genomic Tumor Testing
Clinical Pathology Lab Supports Personalized Medicine
Source Newsroom: Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center
Newswise — (Lebanon, NH, 1/22/14) — Clinical laboratory experts and physicians at Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC) achieved 100 percent accuracy in testing for abnormal DNA in cancerous tumor cells with its new gene sequencing equipment and panels. The results, published in the journal Clinical Chemistry and Laboratory Medicine, confirm the precision of the test for routine patient care so physicians can tailor treatment to an individual person’s DNA, improving the chances of a successful outcome.
“We evaluated next generation tools for gene sequencing in our clinical laboratory,” said Gregory Tsongalis, PhD, director, molecular pathology. “The equipment and approach we are using is faster, more sensitive, and more reliable than previous approaches. It paves the way for routine genetic testing in personalizing cancer care here at the Norris Cotton Cancer Center.”
The genomic sequencing test, called the Ion Torrent AmpliSeq Cancer Hotspot Panel, is often used in research settings. Now the clinically certified and accredited pathology laboratory at NCCC has put in place the ability to routinely perform this test on patient tumor tissue. The NCCC Department of Pathology clinical laboratory, where this testing is performed, is in compliance with the Clinical Laboratory Improvement Amendment (CLIA), which certifies laboratories to federal standards of quality, proficiency, and safety. It is also accredited by the College of American Pathologists, the gold standard in laboratory accreditation.
“This takes genetic sequencing information or molecular profiling of tumors and puts it into the hands of physicians treating patients today,” said Tsongalis.
The laboratory has run over 400 patient samples, about 80 percent of which have identified genetic mutations. About 50 to 60 percent of the tests identify genetic mutations that change the course of treatment. Turnaround time for the test is one week to 10 days. Physicians and scientists test tumor samples from metastatic colon cancer, melanoma, gliomas, and non-small cell lung cancers. In the months to come, they will add testing for breast cancer, leukemia, and lymphoma. Patients' insurance companies reimburse for testing on known mutations as single-gene tests. The Norris Cotton Cancer laboratory, however, runs each sample against a wide panel of genetic mutations. The Cancer Hotspot Panel tests for mutations in 50 common cancer genes as part of a molecular profiling strategy to personalize therapy for an individual patient.
DNA is supposed to be well ordered, and it is considered damaged or mutated when there is an extra or missing section. Genetic mutations can be inherited or caused by environmental factors such as exposure to sunlight, cigarette smoke, or other carcinogens. Damaged DNA can send out the wrong messages to cells: telling them to multiply and grow in ways that can lead to tumors. By identifying the specific mutations in a tumor, physicians can chose medications that precisely target that location for treatment.
About Norris Cotton Cancer Center at Dartmouth-Hitchcock
Norris Cotton Cancer Center combines advanced cancer research at the Geisel School of Medicine at Dartmouth with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center, at Dartmouth-Hitchcock regional locations in Manchester, Nashua, and Keene, NH, and St. Johnsbury, VT, and at 12 partner hospitals throughout New Hampshire and Vermont. It is one of 41 centers nationwide to earn the National Cancer Institute’s “Comprehensive Cancer Center” designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.
Photo caption: The NCCC Department of Pathology clinical laboratory is now able to perform genomic sequencing tests on patient tumor tissue.